All In Biotech

NDA 209899 · Bristol

Zeposia

Ozanimod Hydrochloride · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Aug 30, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Mar 25, 2020

Approved uses

3

Original approval plus efficacy supplements

Registered trials

40

17 Phase 3, 7 recruiting

FAERS reports

8,477

2,297 serious, 91 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 16, 2026.

ZEPOSIA is indicated for the treatment of: relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. moderately to severely active ulcerative colitis (UC) in adults. ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 ) Moderately to severely active ulcerative colitis (UC) in adults. ( 1 )

Mechanism: Ozanimod is a sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5. Ozanimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. Ozanimod has minimal or no activity on S1P 2 , S1P 3 , and S1P 4 . The mechanism by which ozanimod exerts therapeutic effects in multiple sclerosis and ulcerative colitis is unknown but may involve the reduction of lymphocyte migration into the central nervous system and intestine.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ZEPOSIA · OZANIMOD HYDROCHLORIDE EQ 0.23MG BASE · CAPSULE, ORAL · Prescription
  • ZEPOSIA · OZANIMOD HYDROCHLORIDE EQ 0.46MG BASE · CAPSULE, ORAL · Prescription
  • ZEPOSIA · OZANIMOD HYDROCHLORIDE EQ 0.92MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ozanimod" as an intervention, any sponsor and status, largest first.

All 40 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue789
  • multiple sclerosis relapse595
  • drug ineffective553
  • headache526
  • product dose omission issue381
  • dizziness356
  • nausea288
  • diarrhoea267
  • colitis ulcerative263
  • pain259
  • back pain218
  • fall197

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2020243
20211,903
20221,705
20231,533
20241,481
2025995
2026617

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zeposia (Ozanimod Hydrochloride)

2024 spending

$91.0M

Beneficiaries

1,271

8,645 claims

Per beneficiary

$71,559

$292.72 per unit

View as table
YearSpending
2020$2,103,131
2021$19,598,158
2022$37,767,664
2023$62,945,499
2024$90,951,573

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 67 on PubMed

Sponsor: Bristol Myers Squibb

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.